Tiankang: CKBA cream rosacea indication declaration new drug clinical trial acceptance notice.

Taiencon announcement, its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. recently received the acceptance notification issued by the National Medical Products Administration, agreeing to accept the application for phase II/III seamless adaptive clinical trials of CKBA cream for acne rosacea submitted by Bochuangyuan. CKBA cream is a small molecule drug obtained through structural modification and optimization of the lead compound with traditional Chinese medicine frankincense as the active ingredient. It has a new structure, independent intellectual property rights, a clear mechanism of action, and good safety characteristics. CKBA directly targets and inhibits key enzymes ACC1 and ACC2 involved in long chain fatty acid synthesis and metabolism in vitro, regulating the differentiation of nave CD4+ T cells into Th17 cells, significantly reducing IL-17A expression, reducing inflammatory cell infiltration, and improving the typical inflammatory response and erythema of acne rosacea. The application for phase II/III seamless adaptive clinical trials of CKBA cream for acne rosacea has been accepted, and it does not have a significant impact on the company's short-term financial status and operating performance.